Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Acquires 156,091 Shares of Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon acquired 156,091 shares of Electra Therapeutics stock in a transaction that occurred on Thursday, November 5th. The shares were purchased at an average cost of $7.31 per share, with a total value of $1,141,025.21. Following the transaction, the director owned 5,220,762 shares of the company’s stock, valued at approximately $38,163,770.22. The trade was a 3.08% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Electra Therapeutics Stock Performance

NASDAQ ETRA traded down $0.62 on Thursday, reaching $7.35. The stock had a trading volume of 524,786 shares, compared to its average volume of 481,923. Electra Therapeutics, Inc. has a 1 year low of $6.86 and a 1 year high of $15.50.

Analysts Set New Price Targets

Several brokerages recently commented on ETRA. Evercore initiated coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 price target for the company. Zacks Research upgraded shares of Electra Therapeutics to a “hold” rating in a research note on Wednesday, October 14th. Cantor Fitzgerald assumed coverage on shares of Electra Therapeutics in a research report on Tuesday, October 13th. They issued an “overweight” rating for the company. Jefferies Financial Group started coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set a “buy” rating and a $32.00 price target on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of Electra Therapeutics in a research note on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra’s lead investigational product is ELA026, an antibody targeting SIRP?, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.